Christoph Lampert

I am a biopharma executive with 20+ years of experience in oncology, immuno-oncology and translational R&D, currently VP & Site Head at Xilis, where I lead the European subsidiary and am a member of the Executive Leadership Team.

My background spans monoclonal and bispecific antibodies, T-cell engagers, TCR/T-cell therapy and cancer vaccines, with experience building teams, advancing preclinical programs into early clinical development, and translating scientific platforms into value-creating partnerships.

At Hookipa, I built and led preclinical and translational research for the HB-700 KRAS cancer-vaccine program, advancing it to IND-enabling development and materially supporting a strategic Roche partnership valued at up to $930M. Earlier, I led immuno-oncology antibody and T-cell engager programs at Merus and Roche in Zurich.

I am attending the Global Innovation Summit to reconnect with the Swiss biotech and innovation ecosystem as I plan my return to Switzerland into a senior leadership role. I would welcome short conversations with biotech/pharma leaders, investors, board members, executive-search contacts, innovation-platform leaders and venture builders where my oncology, translational and operational background could be relevant.

I am also open to selected discussions around company- and platform-building opportunities in oncology where this experience could create value.